Skip to main content

Table 1 Associations of baseline characteristics with the outcomes among 790 ART-eligible patients.

From: Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa

Variable Started ART Transferred LTFU Died p-value
Total (n = 790) 510 (64.6) 26 (3.3) 136 (17.2) 118 (14.9)  
Sex: (n = 790)      
Male 149 (59.4) 5 (2.0) 48 (19.1) 49 (19.5) 0.025
Female 361 (67.0) 21 (3.9) 88 (16.3) 69 (12.8)  
Age: (n = 790)      
Median in yrs (IQR) 37 (30, 44) 35 (28, 47) 36 (29, 44) 37 (31, 45) 0.549§
<30 116 (62.7) 8 (4.3) 36 (19.5) 25 (13.5) 0.870
30 - 40 217 (66.1) 10 (3.1) 51 (15.6) 50 (15.2)  
>40 177 (63.9) 8 (2.9) 49 (17.7) 43 (15.5)  
HIV type: (n = 790)      
HIV-1 419 (64.8) 18 (2.8) 114 (17.6) 96 (14.8) 0.526Ω
HIV-2 66 (64.0) 7 (6.8) 15 (14.6) 15 (14.6)  
HIV-dual 25 (62.5) 1 (2.5) 7 (17.5) 7 (17.5)  
CD4 count: (n = 788)      
Median in cells/ml (IQR) 150 (80, 240) 235 (190, 290) 130 (65, 200) 95 (40, 172) 0.0001 §
<100 149 (57.8) 2 (0.8) 49 (19.0) 58 (22.4) <0.001
≥100 361 (68.1) 24 (4.5) 87 (16.4) 58 (11.0)  
Occupation: (n = 477)      
Employed 161 (61.9) 9 (3.5) 45 (17.3) 45 (17.3) 0.074
Unemployed 154 (71.0) 4 (1.8) 37 (17.1) 22 (10.1)  
WHO stage: (n = 723)      
1 or 2 425 (64.6) 21 (3.2) 115 (17.5) 97 (14.7)  
3 or 4 33 (50.8) 3 (4.6) 10 (15.4) 19 (29.2) 0.018
  1. Unless otherwise indicated, data are No. (%) of patients in each outcome category
  2. ‡Chi-square test
  3. Ω Fishers exact test
  4. § Kruskall-Wallis test